United States set
Menu Shopping cart $0 Search
Distributed product

IGFBP-3 Total Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Insulin-Like Growth Factor Binding Protein-3
  • Species:Human
Cat. No. Size Price

E03A 96 wells (1 kit) $613,65
PubMed Product Details
Technical Data

Cat # changed from RMEE03A to E03A


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma-Heparin, Cerebrospinal fluid


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.4–30 ng/ml

Limit of Detection

0.1 ng/ml


The kits are CE-IVD certified and intended for professional use.



  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!
  • Quantitative determination of IGFBP-3 without sample pretreatment
  • Inter-Assay variation of 6.30% and Intra-Assay variation of 4.51%
  • Sensitivity of 0.1 ng/ml
  • Measures growth hormone (GH)-dependent IGFBP-3 Bindingprotein
  • 2 Control Sera are provided for quality control purposes according GLP
  • Stable serum levels due to absence of circadian variation
  • Integrates the GH secretory state over days
  • A single measurement is highly informative for diagnosis of GH deficiency or GH excess
  • Ideal for the diagnosis of GH-deficiency in young children
  • Small sample requirement, thus ideal for pediatric patients.

Research topic

Growth hormone and factor-related products


Insulin-like growth factors (IGF)-I and -II are bound to specific binding proteins (IGFBPs) in the circulation. To date,
at least six binding proteins can be distinguished on the basis of their amino acid sequence. They are designated as IGFBP-1, IGFBP-2 to IGPBP-6. Lately the discovery of a new IGFBP-7 has been discussed.
The predominating IGFBP in blood is IGFBP-3, which largely determines the total IGF-I and IGF-II concentration.
In contrast to the other binding proteins, IGFBP-3 has the unique property to associate with an acid-labile
non-binding subunit (ALS) after binding of either IGF-I or IGF-II. Most of the IGFBP-3 in plasma is present as
the high molecular weight ternary complex, however, small amounts of free IGFBP-3 are also found. The development of specific immunoassays for IGFBP-3, recognizing the complete high molecular weight complex,
provided new in-sights into ternary complex regulation. Several factors besides GH influence IGFBP-3 levels: age including sexual development, nutrition, hypothyroidism, diabetes mellitus, liver function and kidney function.
Measurement over 24 hours revealed constant circadian levels.

Product References (2)


  • Jørgensen JO, Blum WF, Møller N, Ranke MB, Christiansen JS. Circadian patterns of serum insulin-like growth factor (IGF) II and IGF binding protein 3 in growth hormone-deficient patients and age- and sex-matched normal subjects. Acta Endocrinol (Copenh). 1990 Sep;123(3):257-62. doi: 10.1530/acta.0.1230257. PubMed PMID: 1700568. See more on PubMed
  • Baxter RC, Cowell CT. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab. 1987 Sep;65(3):432-40. doi: 10.1210/jcem-65-3-432. PubMed PMID: 2442187. See more on PubMed
Summary References (14)

References to IGFBP-3

  • Ballard J, Baxter R, Binoux M, Clemmons D, Drop S, Hall K, Hintz R, Rechler M, Rutanen E, Schwander J. On the nomenclature of the IGF binding proteins. Acta Endocrinol (Copenh). 1989 Nov;121 (5):751-2
  • Baxter RC. Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. J Clin Endocrinol Metab. 1988 Aug;67 (2):265-72
  • Baxter RC, Martin JL. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. J Clin Invest. 1986 Dec;78 (6):1504-12
  • Baxter RC, Martin JL. Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. Proc Natl Acad Sci U S A. 1989 Sep;86 (18):6898-902
  • Blum WF, Ranke MB. Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res. 1990;33 Suppl 4:31-7
  • Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990 May;70 (5):1292-8
  • Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002 Dec;23 (6):824-54
  • Holman SR, Baxter RC. Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation. Growth Regul. 1996 Mar;6 (1):42-7
  • Lee PD, Hintz RL, Sperry JB, Baxter RC, Powell DR. IGF binding proteins in growth-retarded children with chronic renal failure. Pediatr Res. 1989 Oct;26 (4):308-15
  • Schneider MR, Lahm H, Wu M, Hoeflich A, Wolf E. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. FASEB J. 2000 Apr;14 (5):629-40
  • Silha JV, Murphy LJ. Insulin-like growth factor binding proteins in development. Adv Exp Med Biol. 2005;567:55-89
  • Silha JV, Murphy LJ. Insights from insulin-like growth factor binding protein transgenic mice. Endocrinology. 2002 Oct;143 (10):3711-4
  • Wilson EM, Oh Y, Rosenfeld RG. Generation and characterization of an IGFBP-7 antibody: identification of 31kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab. 1997 Apr;82 (4):1301-3
  • Yakar S, Sun H, Zhao H, Pennisi P, Toyoshima Y, Setser J, Stannard B, Scavo L, Leroith D. Metabolic effects of IGF-I deficiency: lessons from mouse models. Pediatr Endocrinol Rev. 2005 Sep;3 (1):11-9
Related Products Docs